Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruthenium(quinoline)2
- Development stage
- Preclinical
- Lead developer
- Pharos University in Alexandria
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
ruthenium(quinoline)2 (Ru(quin)2), chemically known as bis(quinolin-8-olato)bis(triphenylphosphine)ruthenium(II), is a novel ruthenium(II)-based coordination complex incorporating an 8-hydroxyquinoline moiety. It is being investigated as a potential chemotherapeutic agent for the treatment of breast cancer, including estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC). Ru(quin)2 exhibits antiproliferative and cytotoxic activity by inducing apoptosis, stimulating autophagy, and causing cell cycle arrest. Its apoptotic mechanism is associated with the upregulation of BAX, activation of caspase-3, downregulation of Aurora B kinase (AURKB), and histone release. Additionally, it induces autophagy (evidenced by LC3-I to LC3-II conversion and SQSTM1 reduction) and triggers G0/G1 or G2/M cell cycle arrest.
- Other names
- Bis(quinolin-8-olato)bis(triphenylphosphine)ruthenium(II)Bis(quinolin-8-olato)bis(triphenylphosphine)ruthenium(II) complexruthenium(II) complex with 8-hydroxyquinoline
02
Targets
AURKB (Aurora kinase B)DNA
Beyond the preview
Go deeper on ruthenium(quinoline)2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruthenium(quinoline)2.